1
|
Haubrich J, Zwier JM, Charrier-Savournin F, Prézeau L, Pin JP. Different EGF-induced receptor dimer conformations for signaling and internalization. FASEB J 2024; 38:e23356. [PMID: 38071470 DOI: 10.1096/fj.202301209r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 11/13/2023] [Accepted: 11/22/2023] [Indexed: 12/18/2023]
Abstract
The structural basis of the activation and internalization of EGF receptors (EGFR) is still a matter of debate despite the importance of this target in cancer treatment. Whether agonists induce dimer formation or act on preformed dimers remains discussed. Here, we provide direct evidence that EGF-induced EGFR dimer formation as best illustrated by the very large increase in FRET between snap-tagged EGFR subunits induced by agonists. We confirm that Erlotinib-related TK (tyrosine kinase) inhibitors also induce dimer formation despite the inactive state of the binding domain. Surprisingly, TK inhibitors do not inhibit EGF-induced EGFR internalization despite their ability to fully block EGFR signaling. Only Erlotinib-related TK inhibitors promoting asymmetric dimers could slow down this process while the lapatinib-related ones have almost no effect. These results reveal that the conformation of the intracellular TK dimer, rather than the known EGFR signaling, is critical for EGFR internalization. These results also illustrate clear differences in the mode of action of TK inhibitors on the EGFR and open novel possibilities to control EGFR signaling for cancer treatment.
Collapse
Affiliation(s)
- Jordi Haubrich
- Institut de Génomique Fonctionnelle, University of Montpellier, CNRS, INSERM, Montpellier Cedex 5, France
| | | | | | - Laurent Prézeau
- Institut de Génomique Fonctionnelle, University of Montpellier, CNRS, INSERM, Montpellier Cedex 5, France
| | - Jean-Philippe Pin
- Institut de Génomique Fonctionnelle, University of Montpellier, CNRS, INSERM, Montpellier Cedex 5, France
| |
Collapse
|
2
|
Lossaint G, Horvat A, Gire V, Bacevic K, Mrouj K, Charrier-Savournin F, Georget V, Fisher D, Dulic V. Reciprocal regulation of p21 and Chk1 controls the Cyclin D1-RB pathway to mediate senescence onset after G2 arrest. J Cell Sci 2022; 135:274865. [PMID: 35343565 DOI: 10.1242/jcs.259114] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Accepted: 03/18/2022] [Indexed: 11/20/2022] Open
Abstract
Senescence is an irreversible proliferation withdrawal that can be initiated after DNA damage-induced cell cycle arrest in G2 phase to prevent genomic instability. Senescence onset in G2 requires p53 and RB family tumour suppressors, but how they are regulated to convert a temporary cell cycle arrest into a permanent one remains unknown. Here, we show that a previously unrecognised balance between the CDK inhibitor p21 and Chk1 controls D-type cyclin-CDK activity during G2 arrest. In non-transformed cells, p21 activates RB in G2 by inhibiting Cyclin D1-CDK2/CDK4. The resulting G2 exit, which precedes appearance of senescence markers, is associated with a mitotic bypass, Chk1 downregulation and DNA damage foci reduction. In p53/RB-proficient cancer cells, compromised G2 exit correlates with sustained Chk1 activity, delayed p21 induction, untimely Cyclin E1 re-expression and genome reduplication. Conversely, Chk1 depletion promotes senescence by inducing p21 binding to Cyclin D1 and Cyclin E1-CDK complexes and down-regulating CDK6, whereas Chk2 knockdown enables RB phosphorylation and delays G2 exit. In conclusion, p21 and Chk2 oppose Chk1 to maintain RB activity, thus promoting DNA damage-induced senescence onset in G2.
Collapse
Affiliation(s)
| | | | | | | | - Karim Mrouj
- IGMM, Univ. Montpellier, CNRS, Montpellier, France
| | | | - Virginie Georget
- CRBM, Univ. Montpellier, CNRS, Montpellier, France.,Montpellier Ressources Imagerie, BioCampus, University of Montpellier, CNRS, INSERM, Montpellier, France
| | | | | |
Collapse
|
3
|
Zindel D, Mensat P, Vol C, Homayed Z, Charrier-Savournin F, Trinquet E, Banères JL, Pin JP, Pannequin J, Roux T, Dupuis E, Prézeau L. G protein-coupled receptors can control the Hippo/YAP pathway through Gq signaling. FASEB J 2021; 35:e21668. [PMID: 34114695 DOI: 10.1096/fj.202002159r] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Revised: 04/21/2021] [Accepted: 04/30/2021] [Indexed: 11/11/2022]
Abstract
The Hippo pathway is an evolutionarily conserved kinase cascade involved in the control of tissue homeostasis, cellular differentiation, proliferation, and organ size, and is regulated by cell-cell contact, apical cell polarity, and mechanical signals. Miss-regulation of this pathway can lead to cancer. The Hippo pathway acts through the inhibition of the transcriptional coactivators YAP and TAZ through phosphorylation. Among the various signaling mechanisms controlling the hippo pathway, activation of G12/13 by G protein-coupled receptors (GPCR) recently emerged. Here we show that a GPCR, the ghrelin receptor, that activates several types of G proteins, including G12/13, Gi/o, and Gq, can activate YAP through Gq/11 exclusively, independently of G12/13. We revealed that a strong basal YAP activation results from the high constitutive activity of this receptor, which can be further increased upon agonist activation. Thus, acting on ghrelin receptor allowed to modulate up-and-down YAP activity, as activating the receptor increased YAP activity and blocking constitutive activity reduced YAP activity. Our results demonstrate that GPCRs can be used as molecular switches to finely up- or down-regulate YAP activity through a pure Gq pathway.
Collapse
Affiliation(s)
- Diana Zindel
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | | | - Claire Vol
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | - Zeinab Homayed
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | | | | | - Jean-Louis Banères
- Institut des Biomolécules Max Mousseron, Univ. Montpellier, CNRS, Montpellier, France
| | - Jean-Philippe Pin
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | - Julie Pannequin
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| | | | | | - Laurent Prézeau
- Institut de Génomique Fonctionnelle (IGF), Univ. Montpellier, CNRS, INSERM, Montpellier, France
| |
Collapse
|
4
|
Zindel D, Vol C, Lecha O, Bequignon I, Bilgic M, Vereecke M, Charrier-Savournin F, Romier M, Trinquet E, Pin JP, Pannequin J, Roux T, Dupuis E, Prézeau L. HTRF ® Total and Phospho-YAP (Ser127) Cellular Assays. Methods Mol Biol 2019; 1893:153-166. [PMID: 30565133 DOI: 10.1007/978-1-4939-8910-2_13] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
The YAP protein is a co-transcription factor increasing the expression of genes involved in cell proliferation and repressing the expression of genes important for cell differentiation and apoptosis. It is regulated by several inputs, like the Hippo pathway, through the action of kinases that phosphorylate YAP on several residues. The level of phosphorylation of the residues serine 127 (S127) of YAP is generally assessed in cellular models, native tissues, and organs, as a marker of YAP activity and location, and is regulated by numerous partners. This phosphorylation event is classically detected using a western blot technical approach. Here, we describe a novel approach to detect both the relative amount of total YAP (T-YAP assay) and the phosphorylation of the residue S127 of YAP (S127-P-YAP assay) using a HTRF®-based method. This easy-to-run method can easily be miniaturized and allows for a high-throughput analysis in 96/384-well plate format, requiring less cellular material and being more rapid than other approaches.
Collapse
Affiliation(s)
- Diana Zindel
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
| | - Claire Vol
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
| | - Odile Lecha
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
| | | | - Merve Bilgic
- IGF, Univ Montpellier, CNRS, INSERM, Montpellier, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Rivat C, Sar C, Mechaly I, Leyris JP, Diouloufet L, Sonrier C, Philipson Y, Lucas O, Mallié S, Jouvenel A, Tassou A, Haton H, Venteo S, Pin JP, Trinquet E, Charrier-Savournin F, Mezghrani A, Joly W, Mion J, Schmitt M, Pattyn A, Marmigère F, Sokoloff P, Carroll P, Rognan D, Valmier J. Inhibition of neuronal FLT3 receptor tyrosine kinase alleviates peripheral neuropathic pain in mice. Nat Commun 2018. [PMID: 29531216 PMCID: PMC5847526 DOI: 10.1038/s41467-018-03496-2] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
Peripheral neuropathic pain (PNP) is a debilitating and intractable chronic disease, for which sensitization of somatosensory neurons present in dorsal root ganglia that project to the dorsal spinal cord is a key physiopathological process. Here, we show that hematopoietic cells present at the nerve injury site express the cytokine FL, the ligand of fms-like tyrosine kinase 3 receptor (FLT3). FLT3 activation by intra-sciatic nerve injection of FL is sufficient to produce pain hypersensitivity, activate PNP-associated gene expression and generate short-term and long-term sensitization of sensory neurons. Nerve injury-induced PNP symptoms and associated-molecular changes were strongly altered in Flt3-deficient mice or reversed after neuronal FLT3 downregulation in wild-type mice. A first-in-class FLT3 negative allosteric modulator, discovered by structure-based in silico screening, strongly reduced nerve injury-induced sensory hypersensitivity, but had no effect on nociception in non-injured animals. Collectively, our data suggest a new and specific therapeutic approach for PNP. Sensitisation of dorsal root ganglia neurons contributes to neuropathic pain. Here the authors demonstrate the cytokine FL contributes to sensitisation of DRGs via its receptor FLT3 expressed on neurons, and identify a novel FLT3 inhibitor that attenuates neuropathic pain in mice.
Collapse
Affiliation(s)
- Cyril Rivat
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Chamroeun Sar
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Ilana Mechaly
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Jean-Philippe Leyris
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Biodol Therapeutics, Cap Alpha, Clapiers, 34830, France
| | - Lucie Diouloufet
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Corinne Sonrier
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Biodol Therapeutics, Cap Alpha, Clapiers, 34830, France
| | - Yann Philipson
- Laboratoire d'Innovation Thérapeutique, UMR7200, CNRS-Université de Strasbourg, Illkirch, 67400, France
| | - Olivier Lucas
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Sylvie Mallié
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Antoine Jouvenel
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Adrien Tassou
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Henri Haton
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France.,Université de Montpellier, Montpellier, 34000, France
| | - Stéphanie Venteo
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Jean-Philippe Pin
- Institut de Génomique Fonctionnelle, CNRS, INSERM, Univ. Montpellier, 34094, Montpellier, France
| | - Eric Trinquet
- Cisbio Bioassays, Parc Marcel Boiteux, BP84175, 30200, Codolet, France
| | | | - Alexandre Mezghrani
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Willy Joly
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Julie Mion
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Martine Schmitt
- Laboratoire d'Innovation Thérapeutique, UMR7200, CNRS-Université de Strasbourg, Illkirch, 67400, France
| | - Alexandre Pattyn
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Frédéric Marmigère
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | | | - Patrick Carroll
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France
| | - Didier Rognan
- Laboratoire d'Innovation Thérapeutique, UMR7200, CNRS-Université de Strasbourg, Illkirch, 67400, France.
| | - Jean Valmier
- Institute for Neurosciences of Montpellier, INSERM, Institut National de la Santé et de la Recherche Médicale, UMR1051, Hôpital Saint-Eloi, Montpellier, 34000, France. .,Université de Montpellier, Montpellier, 34000, France.
| |
Collapse
|
6
|
Scholler P, Moreno-Delgado D, Lecat-Guillet N, Doumazane E, Monnier C, Charrier-Savournin F, Fabre L, Chouvet C, Soldevila S, Lamarque L, Donsimoni G, Roux T, Zwier JM, Trinquet E, Rondard P, Pin JP. HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat Chem Biol 2017; 13:372-380. [DOI: 10.1038/nchembio.2286] [Citation(s) in RCA: 44] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2016] [Accepted: 11/18/2016] [Indexed: 12/26/2022]
|
7
|
Farino ZJ, Morgenstern TJ, Vallaghe J, Gregor N, Donthamsetti P, Harris PE, Pierre N, Freyberg R, Charrier-Savournin F, Javitch JA, Freyberg Z. Development of a Rapid Insulin Assay by Homogenous Time-Resolved Fluorescence. PLoS One 2016; 11:e0148684. [PMID: 26849707 PMCID: PMC4743966 DOI: 10.1371/journal.pone.0148684] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Accepted: 01/20/2016] [Indexed: 11/29/2022] Open
Abstract
Direct measurement of insulin is critical for basic and clinical studies of insulin secretion. However, current methods are expensive and time-consuming. We developed an insulin assay based on homogenous time-resolved fluorescence that is significantly more rapid and cost-effective than current commonly used approaches. This assay was applied effectively to an insulin secreting cell line, INS-1E cells, as well as pancreatic islets, allowing us to validate the assay by elucidating mechanisms by which dopamine regulates insulin release. We found that dopamine functioned as a significant negative modulator of glucose-stimulated insulin secretion. Further, we showed that bromocriptine, a known dopamine D2/D3 receptor agonist and newly approved drug used for treatment of type II diabetes mellitus, also decreased glucose-stimulated insulin secretion in islets to levels comparable to those caused by dopamine treatment.
Collapse
Affiliation(s)
- Zachary J. Farino
- Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, United States of America
| | - Travis J. Morgenstern
- Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, United States of America
| | | | | | - Prashant Donthamsetti
- Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, United States of America
- Department of Pharmacology, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
| | - Paul E. Harris
- Division of Endocrinology, Department of Medicine, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
| | | | - Robin Freyberg
- Department of Psychology, Stern College for Women, Yeshiva University, New York, New York, United States of America
| | | | - Jonathan A. Javitch
- Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, United States of America
- Department of Pharmacology, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
| | - Zachary Freyberg
- Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York, United States of America
- Division of Molecular Therapeutics, New York State Psychiatric Institute, New York, New York, United States of America
- * E-mail:
| |
Collapse
|
8
|
Ayoub MA, Trebaux J, Vallaghe J, Charrier-Savournin F, Al-Hosaini K, Gonzalez Moya A, Pin JP, Pfleger KDG, Trinquet E. Homogeneous time-resolved fluorescence-based assay to monitor extracellular signal-regulated kinase signaling in a high-throughput format. Front Endocrinol (Lausanne) 2014; 5:94. [PMID: 25002860 PMCID: PMC4066300 DOI: 10.3389/fendo.2014.00094] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/13/2014] [Accepted: 06/04/2014] [Indexed: 01/14/2023] Open
Abstract
The extracellular signal-regulated kinases (ERKs) are key components of multiple important cell signaling pathways regulating diverse biological responses. This signaling is characterized by phosphorylation cascades leading to ERK1/2 activation and promoted by various cell surface receptors including G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs). We report the development of a new cell-based Phospho-ERK1/2 assay (designated Phospho-ERK), which is a sandwich proximity-based assay using the homogeneous time-resolved fluorescence technology. We have validated the assay on endogenously expressed ERK1/2 activated by the epidermal growth factor as a prototypical RTK, as well as various GPCRs belonging to different classes and coupling to different heterotrimeric G proteins. The assay was successfully miniaturized in 384-well plates using various cell lines endogenously, transiently, or stably expressing the different receptors. The validation was performed for agonists, antagonists, and inhibitors in dose-response as well as kinetic analysis, and the signaling and pharmacological properties of the different receptors were reproduced. Furthermore, the determination of a Z'-factor value of 0.7 indicates the potential of the Phospho-ERK assay for high-throughput screening of compounds that may modulate ERK1/2 signaling. Finally, our study is of great interest in the current context of investigating ERK1/2 signaling with respect to the emerging concepts of biased ligands, G protein-dependent/independent ERK1/2 activation, and functional transactivation between GPCRs and RTKs, illustrating the importance of considering the ERK1/2 pathway in cell signaling.
Collapse
Affiliation(s)
- Mohammed Akli Ayoub
- Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, WA, Australia
| | | | | | | | - Khaled Al-Hosaini
- Department of Molecular Pharmacology, CNRS UMR5203, INSERM U661, Institute of Functional Genomics, Universities Montpellier 1 & 2, Montpellier, France
| | | | - Jean-Philippe Pin
- Department of Molecular Pharmacology, CNRS UMR5203, INSERM U661, Institute of Functional Genomics, Universities Montpellier 1 & 2, Montpellier, France
| | - Kevin D. G. Pfleger
- Molecular Endocrinology and Pharmacology, Harry Perkins Institute of Medical Research and Centre for Medical Research, The University of Western Australia, Nedlands, WA, Australia
| | | |
Collapse
|
9
|
Zwier JM, Roux T, Cottet M, Durroux T, Douzon S, Bdioui S, Gregor N, Bourrier E, Oueslati N, Nicolas L, Tinel N, Boisseau C, Yverneau P, Charrier-Savournin F, Fink M, Trinquet E. A fluorescent ligand-binding alternative using Tag-lite® technology. ACTA ACUST UNITED AC 2010; 15:1248-59. [PMID: 20974902 DOI: 10.1177/1087057110384611] [Citation(s) in RCA: 108] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
G-protein-coupled receptors (GPCRs) are crucial cell surface receptors that transmit signals from a wide range of extracellular ligands. Indeed, 40% to 50% of all marketed drugs are thought to modulate GPCR activity, making them the major class of targets in the drug discovery process. Binding assays are widely used to identify high-affinity, selective, and potent GPCR drugs. In this field, the use of radiolabeled ligands has remained so far the gold-standard method. Here the authors report a less hazardous alternative for high-throughput screening (HTS) applications by the setup of a nonradioactive fluorescence-based technology named Tag-lite(®). Selective binding of various fluorescent ligands, either peptidic or not, covering a large panel of GPCRs from different classes is illustrated, particularly for chemokine (CXCR4), opioid (δ, µ, and κ), and cholecystokinin (CCK1 and CCK2) receptors. Affinity constants of well-known pharmacological agents of numerous GPCRs are in line with values published in the literature. The authors clearly demonstrate that the Tag-lite binding assay format can be successfully and reproducibly applied by using different cellular materials such as transient or stable recombinant cells lines expressing SNAP-tagged GPCR. Such fluorescent-based binding assays can be performed with adherent cells or cells in suspension, in 96- or 384-well plates. Altogether, this new technology offers great advantages in terms of flexibility, rapidity, and user-friendliness; allows easy miniaturization; and makes it completely suitable for HTS applications.
Collapse
|
10
|
Gras S, Chaumont V, Fernandez B, Carpentier P, Charrier-Savournin F, Schmitt S, Pineau C, Flament D, Hecker A, Forterre P, Armengaud J, Housset D. Structural insights into a new homodimeric self-activated GTPase family. EMBO Rep 2007; 8:569-75. [PMID: 17468740 PMCID: PMC2002535 DOI: 10.1038/sj.embor.7400958] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2006] [Revised: 01/25/2007] [Accepted: 02/28/2007] [Indexed: 11/09/2022] Open
Abstract
The human XAB1/MBDin GTPase and its close homologues form one of the ten phylogenetically distinct families of the SIMIBI (after signal recognition particle, MinD and BioD) class of phosphate-binding loop NTPases. The genomic context and the partners identified for the archaeal and eukaryotic homologues indicate that they are involved in genome maintenance--DNA repair or replication. The crystal structure of PAB0955 from Pyrococcus abyssi shows that, unlike other SIMIBI class G proteins, these highly conserved GTPases are homodimeric, regardless of the presence of nucleotides. The nucleotide-binding site of PAB0955 is rather rigid and its conformation is closest to that of the activated SRP G domain. One insertion to the G domain bears a strictly conserved GPN motif, which is part of the catalytic site of the other monomer and stabilizes the phosphate ion formed. Owing to this unique functional feature, we propose to call this family as GPN-loop GTPase.
Collapse
Affiliation(s)
- Stéphanie Gras
- Laboratoire de Cristallographie et Cristallogénèse des Protéines, Institut de Biologie Structurale J.-P. Ebel, CEA-CNRS-UJF, UMR 5075, 41, Rue Jules Horowitz, F-38027 Grenoble, France
| | - Valérie Chaumont
- Laboratoire de Biochimie des Systèmes Perturbés, Service de Biochimie et Toxicologie Nucléaire, Institut de Biologie Environnementale et Biotechnologie, CEA-VALRHO, Marcoule, BP 17171, F-30207 Bagnols sur Cèze, France
| | - Bernard Fernandez
- Laboratoire de Biochimie des Systèmes Perturbés, Service de Biochimie et Toxicologie Nucléaire, Institut de Biologie Environnementale et Biotechnologie, CEA-VALRHO, Marcoule, BP 17171, F-30207 Bagnols sur Cèze, France
| | - Philippe Carpentier
- Laboratoire de Cristallographie et Cristallogénèse des Protéines, Institut de Biologie Structurale J.-P. Ebel, CEA-CNRS-UJF, UMR 5075, 41, Rue Jules Horowitz, F-38027 Grenoble, France
| | - Fabienne Charrier-Savournin
- Laboratoire de Biochimie des Systèmes Perturbés, Service de Biochimie et Toxicologie Nucléaire, Institut de Biologie Environnementale et Biotechnologie, CEA-VALRHO, Marcoule, BP 17171, F-30207 Bagnols sur Cèze, France
| | - Sophie Schmitt
- Laboratoire de Microbiologie des Environnements Extrêmes, UMR6197, IFREMER-Centre de Brest, BP 70, F-29280 Plouzané cedex, France
| | - Charles Pineau
- INSERM, U625, UPRES JE 2459, Campus de Beaulieu, Rennes F-35042, France
| | - Didier Flament
- Laboratoire de Microbiologie des Environnements Extrêmes, UMR6197, IFREMER-Centre de Brest, BP 70, F-29280 Plouzané cedex, France
| | - Arnaud Hecker
- UMR CNRS/Université Paris-Sud 8621, Institut de Génétique et de Microbiologie – Bât. 409, F-91405 Orsay cedex, France
| | - Patrick Forterre
- UMR CNRS/Université Paris-Sud 8621, Institut de Génétique et de Microbiologie – Bât. 409, F-91405 Orsay cedex, France
- Laboratoire de Microbiologie et de Biotechnologie des Extremophiles, Département de Microbiologie Fondamentale et Médicale, Institut Pasteur, 28 Rue du Dr Roux, F-75724 Paris cedex 15, France
| | - Jean Armengaud
- Laboratoire de Biochimie des Systèmes Perturbés, Service de Biochimie et Toxicologie Nucléaire, Institut de Biologie Environnementale et Biotechnologie, CEA-VALRHO, Marcoule, BP 17171, F-30207 Bagnols sur Cèze, France
| | - Dominique Housset
- Laboratoire de Cristallographie et Cristallogénèse des Protéines, Institut de Biologie Structurale J.-P. Ebel, CEA-CNRS-UJF, UMR 5075, 41, Rue Jules Horowitz, F-38027 Grenoble, France
- Tel: +33 4 76 20 94 69; Fax: +33 4 38 78 51 22; E-mail:
| |
Collapse
|